Completed PHASE4 INTERVENTIONAL 2-arm
NCT07230184
To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR
To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With Non-proliferative Diabetic Retinopathy (NPDR), Focusing on Changes in Hard Exudates (HE) Over 24 Weeks.
Sponsor: AJU Pharm Co., Ltd.
Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
B55R1 and B55R2 B55R1 and placebo for B55R2
Updated 1 time since 2025 Last updated: Nov 14, 2025 Started: Apr 28, 2022 Primary completion: Aug 14, 2023 Completion: Aug 16, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE4 clinical study on Non-Proliferative Diabetic Retinopathy, this trial is completed. The trial is conducted by AJU Pharm Co., Ltd. and has accumulated 1 data snapshot since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Completed — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- AJU Pharm Co., Ltd.
Data source: AJU Pharm Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .